The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a greater substantial loss in body weight and improve metabolic function, par